FDA today announced that efalizumab (Raptiva)

[tropical]

FDA Issues Boxed Warning for Efalizumab
ROCKVILLE, Md. -- The FDA today announced that efalizumab (Raptiva)
must carry a boxed warning to highlight the risk of life-threatening
infections, including progressive multifocal leukoencephalopathy
(PML). full story
http://www.medpagetoday.com/InfectiousDisease/PublicHealth/11358

 

[mixin]

Re: FDA today announced that efalizumab (Raptiva)

The warning will also include an increased risk of bacterial sepsis, viral meningitis, and invasive fungal disease.

Truly, a consumer needs to be educated on all potential side effects on these drugs. Maybe they only occur rarely, but the pros and cons of taking medication with such serious side effects need to be considered.

Here is my favorite site for drug information http://www.rxlist.com/cgi/generic/raptiva.htm

 

[tropical]

Re: FDA today announced that efalizumab (Raptiva)

#1;2:
"the risk of life-threatening infections, including progressive multifocal leukoencephalopathy
"The warning will also include an increased risk of bacterial sepsis, viral meningitis, and invasive fungal disease."

Thanks mixin,
Apaling and distressing indeed.

We can see that those new medications which are not yet individualy designed, can carry up many unaceptable illnesses.

"Recombinant" through lab. tryings can be a mix of naturaly unmixable components with parts of microbes/etc.
(we saw through the melamine and acid stuff what unespectable effects apeared only from chemicals).
Such unnatural biochem. mix obviously are some way able to stimulate the insurgence of deadly illnesses at the same time with its treatment purposes.

We never even think of the live animal eshalons sacrificed to experimental tryings, but now we are on that table also ...

___
"From the link at #2:
Definition of Recombinant

http://www.rxlist.com/script/main/art.asp?articlekey=5244

Recombinant: A person with a new combination of genes, a combination of genes not present in either parent, due to parental recombination of those genes.
Source: MedTerms? Medical Dictionary
http://www.medterms.com/script/main/art.asp?articlekey=5244
___
DRUG DESCRIPTION

RAPTIVA? (efalizumab) is an immunosuppressiverecombinant humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a (1). Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not detectable in the final product.
RAPTIVA is supplied as a sterile, white to off-white, lyophilized powder in single-use glass vials for subcutaneous (SC) injection. Reconstitution of the single-use vial with 1.3 mL of the supplied sterile water for injection (non-USP) yields approximately 1.5 mL of solution to deliver 125 mg per 1.25 mL (100 mg/mL) of RAPTIVA. The sterile water for injection supplied does not comply with USP requirement for pH. After reconstitution, RAPTIVA is a clear to pale yellow solution with a pH of approximately 6.2. Each single-use vial of RAPTIVA contains 150 mg of efalizumab, 123.2 mg of sucrose, 6.8 mg of L-histidine hydrochloride monohydrate, 4.3 mg of L-histidine and 3 mg of polysorbate 20 and is designed to deliver 125 mg of efalizumab in 1.25 mL.
Brand Name: Raptiva
Generic Name: Efalizumab"